Company Description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service.
It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Country | Denmark |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,379 |
| CEO | Dr. Paul John Chaplin MSc, Ph.D. |
Contact Details
Address: Bageskovvej 9 Dk-3490 Kvistgaard, G7 00000 Denmark | |
| Phone | 45033268383 |
| Website | bavarian-nordic.com |
Stock Details
| Ticker Symbol | BVNRY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001328132 |
| ISIN Number | US0717711099 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | Chief Executive Officer and President |
| Henrik Juuel M.Sc. | Chief Financial Officer and Executive Vice President |
| Russell Thirsk M.Sc. | Executive Vice President and Chief Operating Officer |
| Rolf Sass Sørensen | Vice President of Investor Relations and Communications |
| Anu Helena Kerns M.Sc. | Executive Vice President and Chief People and Sustainability Officer |
| Jean-Christophe May M.B.A., Pharm.D. | Executive Vice President and Chief Commercial Officer |
| Dr. Laurence De Moerlooze Ph.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2007 | F-X | Filing |
| Feb 21, 2007 | CB | Filing |
| May 23, 2005 | F-X | Filing |
| May 23, 2005 | CB | Filing |